Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25771926
DOI
10.1038/ijo.2015.28
PII: ijo201528
Knihovny.cz E-zdroje
- MeSH
- energetický metabolismus MeSH
- hormon uvolňující prolaktin analogy a deriváty farmakologie MeSH
- látky proti obezitě farmakologie MeSH
- lipidy chemie MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- obezita prevence a kontrola MeSH
- poločas MeSH
- přijímání potravy MeSH
- regulace chuti k jídlu MeSH
- signální transdukce MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- hormon uvolňující prolaktin MeSH
- látky proti obezitě MeSH
- lipidy MeSH
OBJECTIVES: Obesity is a frequent metabolic disorder but an effective therapy is still scarce. Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity but are ineffective after peripheral application. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both PrRP- and PrRP-receptor-knockout mice. RESULTS: Lipidized PrRP analogs showed binding affinity and signaling in PrRP receptor-expressing cells similar to natural PrRP. Moreover, these analogs showed high binding affinity also to anorexigenic neuropeptide FF-2 receptor. Peripheral administration of myristoylated and palmitoylated PrRP analogs to fasted mice induced strong and long-lasting anorexigenic effects and neuronal activation in the brain areas involved in food intake regulation. Two-week-long subcutaneous administration of palmitoylated PrRP31 and myristoylated PrRP20 lowered food intake, body weight and improved metabolic parameters, and attenuated lipogenesis in mice with diet-induced obesity. CONCLUSIONS: Our data suggest that the lipidization of PrRP enhances stability and mediates its effect in central nervous system. Strong anorexigenic and body-weight-reducing effects make lipidized PrRP an attractive candidate for anti-obesity treatment.
3rd Department of Medicine Charles University Prague Prague Czech Republic
Antiobesity Peptides Institute of Organic Chemistry and Biochemistry AS CR Prague Czech Republic
Department of Analytical Chemistry University of Chemistry and Technology Prague Czech Republic
Zobrazit více v PubMed
Brain Res. 2004 Jul 16;1014(1-2):61-70 PubMed
Nature. 1998 May 21;393(6682):272-6 PubMed
Pharm Res. 2004 Aug;21(8):1498-504 PubMed
Neurochem Int. 2011 Nov;59(6):889-95 PubMed
Peptides. 2007 Oct;28(10):1945-53 PubMed
Endocrinology. 2002 Feb;143(2):360-7 PubMed
Trends Pharmacol Sci. 2010 Sep;31(9):434-41 PubMed
Physiol Behav. 2013 Sep 10;121:35-42 PubMed
Curr Protoc Neurosci. 2002 Aug;Chapter 7:Unit 7.5 PubMed
Brain Res. 2013 Mar 1;1498:33-40 PubMed
Biochem Biophys Res Commun. 2007 Nov 23;363(3):633-8 PubMed
Neuroendocrinology. 2000 Apr;71(4):262-7 PubMed
Endocrinology. 2006 Jul;147(7):3190-5 PubMed
Peptides. 2011 Sep;32(9):1887-92 PubMed
Physiol Res. 2013;62(4):435-44 PubMed
Clin Sci (Lond). 2011 Aug;121(3):107-17 PubMed
Neurosci Res. 2000 Nov;38(3):223-30 PubMed
Endocrinology. 2006 Oct;147(10):4723-9 PubMed
Mol Cell Endocrinol. 2011 Aug 22;343 (1-2):55-62 PubMed
Neuropeptides. 2011 Oct;45(5):309-16 PubMed
Peptides. 2011 Apr;32(4):811-7 PubMed
Peptides. 2006 May;27(5):1110-20 PubMed
Prog Neurobiol. 2009 Apr;87(4):212-51 PubMed
Diabetes Obes Metab. 2010 Oct;12(10):891-9 PubMed
Front Endocrinol (Lausanne). 2013 Mar 05;4:20 PubMed
Exp Physiol. 2004 May;89(3):229-35 PubMed
Biochem Pharmacol. 2010 Aug 1;80(3):396-401 PubMed
J Pharmacol Exp Ther. 2012 Mar;340(3):781-6 PubMed
Am J Physiol. 1996 May;270(5 Pt 1):E768-75 PubMed
Nat Neurosci. 2000 Jul;3(7):645-6 PubMed
Brain Res. 2014 Feb 14;1547:16-24 PubMed
Biochem Pharmacol. 1978;27(19):2297-300 PubMed
Eur J Pharmacol. 1992 Nov 10;222(2-3):233-40 PubMed
BMC Neurosci. 2008 Oct 21;9:101 PubMed
Endocrinology. 1999 Dec;140(12):5736-45 PubMed
J Pharmacol Exp Ther. 2003 Jun;305(3):825-32 PubMed
Peptides. 2013 Jan;39:138-44 PubMed
J Clin Invest. 2008 Dec;118(12):4014-24 PubMed
Endocrinology. 2001 May;142(5):2032-8 PubMed
Ther Adv Chronic Dis. 2014 May;5(3):135-48 PubMed
J Pept Sci. 2005 Mar;11(3):161-5 PubMed
An analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis
Lipidization as a tool toward peptide therapeutics
High-Fat Diet Induces Resistance to Ghrelin and LEAP2 Peptide Analogs in Mice
NPFFR2-deficient mice fed a high-fat diet develop strong intolerance to glucose
Prolactin-Releasing Peptide: Physiological and Pharmacological Properties